Fulgent Genetics Full Year 2024 Earnings: Eps Beats Expectations
Fulgent Genetics' full-year 2024 earnings report shows revenue down 2.0% from FY 2023, but the company's loss narrowed by 75%, with a net loss of US$42.7m and a loss per share of US$1.41. The company's earnings per share (EPS) surpassed analyst estimates by 17%. Fulgent Genetics forecasts revenue growth of 11% p.a. on average during the next 2 years, outpacing the Healthcare industry in the US at 7.1%.
- The fact that Fulgent Genetics' loss narrowed by 75% is a positive sign for the company's financial health and suggests that it may be gaining traction in its business operations.
- Will this growth translate to increased investor confidence, potentially leading to higher stock prices, or will market sentiment remain cautious given the company's history of losses?